Overview

Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study

Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the feasibility of adding induction and maintenance Avelumab to the standard combination of R-CHOP in patients with stage II, III and IV diffuse large B cell lymphoma (DLBCL)
Phase:
Early Phase 1
Details
Lead Sponsor:
Austin Health
Collaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Treatments:
Avelumab